Angiogenesis in glioma: Molecular mechanisms and roadblocks to translation

Cancer Journal

Volumn 9, Issue 3, 2003, Pages 205-213

  Bögler, Oliver ^a   Mikkelsen, Tom ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Angiogenesis; Astrocytoma; Blood vessels; Glioma; Magnetic resonance imaging

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 4 DEDIMETHYLAMINOSANCYCLINE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CAPTOPRIL; CC 7085; CDC 801; CILENGITIDE; COMBRETASTATIN A4; CYCLOPEPTIDE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ENDOSTATIN; FLAVONOID; FLUOROURACIL; GELDANAMYCIN; LENALIDOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; MONOCLONAL ANTIBODY LM 609; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PRINOMASTAT; REBIMASTAT; SOLIMASTAT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VINBLASTINE;

ANGIOGENESIS; ASTROCYTOMA; BLOOD FLOW; BLOOD VESSEL; BRAIN TUMOR; CLINICAL TRIAL; DIAGNOSTIC IMAGING; GLIOBLASTOMA; GLIOMA; HUMAN; IMAGING SYSTEM; MEDICAL RESEARCH; MOLECULAR DYNAMICS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TREATMENT RESPONSE; TUMOR GROWTH; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 0642336106     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200305000-00008     Document Type: Review

References (85)

1. Kleihues P, Burger PC, Collins VP et al. Glioblastoma Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000: 88-89.
2. Brat DJ, Van Meir EG. Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 2001;158:789-796.
3. Yancopoulos GD, Davis S, Gale NW et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248.
4. Morimoto T, Aoyagi M, Tamaki M et al. Increased levels of tissue endostatin in human malignant gliomas. Clin. Cancer Res 2002;8:2933-2938.
5. Brat DJ, Kaur B, Van Meir EG. Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 2003;8:D100-D116.
6. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-416.
7. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995;15:339-347.
8. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis Am J Physiol [Cell Physiol] 2002;282:C947-C970.
9. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
10. Takano S, Yoshii Y, Kondo S et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996;56:2185-2190.
11. Schmidt NO, Westphal M, Hagel C et al. Levels of vascular endothelial growth factor hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10-18.
12. Cheng SY, Huang HJ, Nagane M et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996;93:8502-8507.
13. Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997;94:12081-12087.
14. Achen MG, Jeltsch M, Kukk E et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998;95:548-553.
15. Joukov V, Kaipainen A, Jeltsch M et al. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol 1997;173:211-215.
16. Sundberg C, Nagy JA, Brown LF et al. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 2001;158:1145-1160.
17. Zadeh G, Guha A. Neoangiogenesis in human astrocytomas: expression and functional role of angiopoietins and their cognate receptors. Front Biosci 2003;8:E128-E137.
18. Ding H, Roncari L, Wu X et al. Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro-oncol 2001;3:1-10.
19. Ratel D, Nasser V, Dupre I et al. Antibodies to endostatin in a multifocal glioblastoma patient. Lancet 2000;356:1656-1657.
20. Tenan M, Fulci G, Albertoni M et al. Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med 2000;191:1789-1798.
21. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001;7:401-407.
22. Kragh M, Quistorff B, Tenan M et al. Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma. Cancer Res 2002;62:1191-1195.
23. Kung AL, Wang S, Klco JM et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6:1335-1340.
24. Mabjeesh NJ, Post DE, Willard MT et al. Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-2482.
25. Rapisarda A, Uranchimeg B, Scudiero DA et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002;62:4316-4324
26. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-1807.
27. Pore N, Liu S, Haas-Kogan DA et al. PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003;63:236-241.
28. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
29. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
30. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
31. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
32. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents J Neurooncol 2000;46:135-144
33. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
34. Lew YS, Kolozsvary A, Brown SL, Kim JH. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 2002;62:4202-4205.
35. Lew YS, Brown SL, Griffin RJ et al. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-6037.
36. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
37. Jones MK, Wang H, Peskar B et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-1423.
38. Jacobs W, Mikkelsen T, Smith R et al. Inhibitory effects of CAI in glioblastoma growth and invasion. J Neurooncol 1997;32:93-101.
39. Matsubara T, Saura R, Hirohata K, Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J Clin Invest 1989;83:158-167.
40. Brewer GJ, Dick RD, Grover DK et al. Treatment of metastatic cancer with tetrathiomolybdate an anticopper antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6:1-10.
41. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20:4478-4484.
42. O'Reilly MS. The combination of antiangiogenic therapy with other modalities Cancer J 2002;8 (Suppl 1):S89-S99.
43. O'Reilly MS. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin Cancer Res 2002;8:3309-3310.
44. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440.
45. Herbst RS, Mullani NA, Davis DW et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002;20:3804-3814.
46. Beliveau R, Gingras D, Kruger EA et al.The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 2002;8:1242-1250.
47. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-1201.
48. Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958.
49. Gehling UM, Ergun S, Schumacher U et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106-3112.
50. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
51. Clarke LP, Velthuizen RP, Clark M et al. MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magn Reson Imaging 1998;16:271-279.
52. Vaidyanathan M, Clarke LP, Velthuizen RP et al. Comparison of supervised MRI segmentation methods for tumor volume determination during therapy. Magn Reson Imaging 1995;13:719-728.
53. Velthuizen RP, Hall LO, Clarke LP. Feature extraction for MRI segmentation. J Neuroimaging 1999;9:85-90.
54. Sipkins DA, Cheresh DA, Kazemi MR et al. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted. Magnetic resonance imaging. Nat Med 1998;4:623-626.
55. Anderson SA, Rader RK, Westlin WF et al. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med 2000;44:433-439.
56. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
57. Gossmann A, Helbich TH, Kuriyama N et al. Dynamic contrast-enhanced. Magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-240.
58. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
59. Barentsz JO, Engelbrecht M, Jager GJ et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 1999;10:295-304.
60. Hawighorst H, Libicher M, Knopp MV et al. Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging 1999;10:286-294.
61. Knopp MV, Weiss E, Sinn HP et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-266.
62. Mayr NA, Hawighorst H, Yuh WT et al. MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging 1999;10:267-276.
63. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-6815.
64. Ostergaard L, Sorensen AG, Kwong KK et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages Part II: Experimental comparison and preliminary results. Magn Reson Med 1996;36:726-736.
65. Ostergaard L, Weisskoff RM, Chesler DA, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages Part I: Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
66. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-265.
67. Taylor JS, Tofts PS, Port R et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 1999;10:903-907.
68. Koshimoto Y, Yamada H, Kimura H et al. Quantitative analysis of cerebral microvascular hemodynamics with T2-weighted dynamic MR imaging. J Magn Reson Imaging 1999;9:462-467.
69. Dennie J, Mandeville JB, Boxerman JL et al. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-799.
70. Lev MH, Hochberg F. Perfusion. Magnetic resonance imaging to assess brain tumor responses to new therapies cancer control 1998;5:115-123.
71. Zaharchuk G, Bogdanov AA Jr, Marota JJ et al. Continuous assess-ment of perfusion by tagging including volume and water extraction (CAPTIVE): a steady-state contrast agent technique for measuring blood flow relative blood volume fraction and the water extraction fraction. Magn Reson Med 1998;40:666-678.
72. Siegal T, Rubinstein R, Tzuk-Shina T, Gomori JM. Utility of relative cerebral blood volume mapping derived from perfusion. Magnetic resonance imaging in the routine follow up of brain tumors. J Neurosurg 1997;86:22-27.
73. Lev MH, Rosen BR. Clinical applications of intracranial perfusion MR imaging. Neuroimaging Clin N Am 1999;9:309-331.
74. van der Sanden BP, Rozijn H, Rijken PF et al. Noninvasive assessment of the functional neovasculature in 9L-glioma growing in rat brain by dynamic 1H. Magnetic resonance imaging of gadolinium uptake. J Cereb Blood Flow Metab 2000;20:861-870.
75. Tynninen O, Aronen HJ, Ruhala M et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. Invest Radiol 1999;34:427-434.
76. Aronen HJ, Gazit IE, Louis DN et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
77. Li KL, Zhu XP, Waterton J, Jackson A. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 2000;12:347-357.
78. Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating superparamagnetic iron oxide agent. J Magn Reson Imaging 1999;9:228-232.
79. Loubeyre P, Zhao S, Canet E et al. Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: experimental study in rabbits. J Magn Reson Imaging 1997;7:958-962.
80. Loubeyre P, De Jaegere T, Bosmans H et al. Comparison of iron oxide particles (AMI 227) with a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) for both phantom and rat brain at 15 Tesla. J Magn Reson Imaging 1999;9:447-453.
81. Loubeyre P, de Jaegere T, Miao Y et al. Assessment of iron oxide particles (AMI 227) and a gadolinium complex (Gd-DOTA) in dynamic susceptibility contrast MR imagings (FLASH and EPI) in a tumor model implanted in rats. Magn Reson Imaging 1999;17:627-631.
82. Simonsen CZ, Ostergaard L, Vestergaard-Poulsen P et al. CBF and CBV measurements by USPIO bolus tracking: reproducibility and comparison with Gd-based values. J Magn Reson Imaging 1999;9:342-347.
83. Sharma R, Saini S, Ros PR et al. Safety profile of ultrasmall super-paramagnetic iron oxide ferumoxtran-10: phase II clinical trial data. J Magn Reson Imaging 1999;9:291-294.
84. Weissleder R, Cheng HC, Marecos E et al. Non-invasive in vivo mapping of tumour vascular and interstitial volume fractions. Eur J Cancer 1998;34:1448-1454.
85. Pathak AP, Schmainda KM, Ward BD et al. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001;46:735-747.